查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703282

HIV 診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、按檢測類型（抗體檢測、病毒載量檢測、CD4 檢測等）、按模式、按最終用途、按地區和競爭情況細分，2020 年至 2030 年

HIV Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Test Type (Antibody Tests, Viral Load Tests, CD4 Test, Others), By Mode, By End-use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 HIV 診斷市場價值為 45.3 億美元，預計到 2030 年將達到 74.7 億美元，年複合成長率(CAGR) 為 8.68%。自 20 世紀 80 年代初愛滋病出現以來，愛滋病毒診斷領域發生了重大變化。診斷技術的進步、公眾意識的提高以及更廣泛的檢測機會在全球應對愛滋病毒/愛滋病疫情中發揮了關鍵作用。如今，愛滋病毒診斷領域是一個充滿活力且快速發展的行業，為改善疾病管理並最終根除疾病帶來了新的希望。

市場概覽
預測期 2026-2030
2024年市場規模 45.3億美元
2030年市場規模 74.7億美元
2025-2030 年複合年成長率 8.68%
成長最快的領域 抗體測試
最大的市場 北美洲

HIV（人類免疫缺乏病毒）透過攻擊對於抵抗感染至關重要的 CD4 細胞來損害免疫系統。如果不及時治療，愛滋病毒會發展為愛滋病（後天免疫缺乏症候群），增加機會性感染和某些癌症的可能性。儘管不斷做出努力，全球愛滋病毒/愛滋病疫情仍然是一個緊迫的公共衛生問題，全世界數百萬人受到影響。根據聯合國愛滋病規劃署統計，截至 2019 年，全球約有 3,800 萬人感染愛滋病毒。雖然在降低感染率和愛滋病相關死亡率方面取得了進展，但持續存在的挑戰凸顯了可近性、準確的診斷方法對於減輕病毒影響的重要性。

市場促進因素

愛滋病毒感染率上升推動診斷需求

市場挑戰

無障礙和認知障礙

市場趨勢

技術創新推動市場擴張

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球愛滋病毒診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按產品（耗材、儀器、軟體和服務）
    • 依檢測類型（抗體檢測（HIV-1 篩檢檢測、HIV-1 抗體確認檢測、HIV-2 和 O 組診斷檢測）、病毒量檢測、CD4 檢測、其他）
    • 按模式（自測、基於實驗室）
    • 依最終用途（診斷實驗室、醫院和診所、家庭環境）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美HIV診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲HIV診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區愛滋病毒診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲愛滋病毒診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲愛滋病毒診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Thermo Fisher Scientific, Inc.
  • Alere Inc.
  • Abbott Laboratories inc.
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • VIIV Healthcare
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Zyomtronix, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16747

Global HIV Diagnostics market was valued at USD 4.53 billion in 2024 and is projected to reach USD 7.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.68%. Since the emergence of AIDS in the early 1980s, the HIV diagnostics landscape has evolved significantly. Advances in diagnostic technologies, increased public awareness, and broader access to testing have all played pivotal roles in the global response to the HIV/AIDS epidemic. Today, the HIV diagnostics sector represents a dynamic and rapidly advancing industry, offering renewed hope for improved disease management and, ultimately, eradication.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.53 Billion
Market Size 2030USD 7.47 Billion
CAGR 2025-20308.68%
Fastest Growing SegmentAntibody Tests
Largest MarketNorth America

HIV (Human Immunodeficiency Virus) compromises the immune system by targeting CD4 cells, critical to defending against infections. Without timely treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), increasing vulnerability to opportunistic infections and certain cancers. Despite ongoing efforts, the global HIV/AIDS epidemic remains a pressing public health concern, with millions affected worldwide. According to UNAIDS, approximately 38 million individuals were living with HIV as of 2019. While progress has been made in reducing infection rates and AIDS-related mortality, persistent challenges underscore the importance of accessible, accurate diagnostics in mitigating the virus's impact.

Market Drivers

Rising HIV Prevalence Fueling Demand for Diagnostics

The growing global prevalence of HIV/AIDS continues to be a major driver of the HIV diagnostics market. As per the World Health Organization (WHO), around 39.9 million people were living with HIV at the end of 2023, with Sub-Saharan Africa remaining the most affected region, accounting for over two-thirds of global cases. However, HIV continues to affect populations worldwide, reinforcing the universal demand for reliable diagnostic solutions.

Despite preventive measures and treatment advancements, the incidence of new HIV infections remains concerning. In 2023 alone, an estimated 1.3 million individuals acquired HIV. Contributing factors include limited access to preventive education, lack of contraceptive availability, and ongoing social stigma, which impedes testing and treatment efforts. The growing global population also means a rise in the absolute number of individuals living with HIV, thereby intensifying the need for early detection and clinical management.

Timely diagnosis is essential for initiating antiretroviral therapy (ART), which improves quality of life and reduces the risk of transmission. Early detection also helps prevent disease progression to AIDS, subsequently lowering mortality rates. In 2023, AIDS-related illnesses claimed approximately 630,000 lives worldwide. As such, the increasing burden of HIV has bolstered the demand for robust diagnostic tools, reinforcing their role in treatment planning, prevention, and public health management.

Market Challenges

Barriers to Accessibility and Awareness

Despite advancements, significant challenges persist, particularly in low- and middle-income countries where healthcare systems often lack the resources necessary for effective HIV diagnosis. In many rural and underserved areas, diagnostic services are limited due to poor infrastructure, inadequate transportation, and a shortage of trained medical personnel. These systemic gaps lead to late diagnoses and delayed treatment initiation.

Even in areas where diagnostic tools are available, factors such as inconsistent electricity supply, inadequate refrigeration for test kits, and substandard sanitary conditions compromise test accuracy. Moreover, social stigma, fear of discrimination, and misinformation continue to deter individuals from seeking testing. Misperceptions about personal risk and reluctance to discuss sexual health further hinder diagnosis efforts. In regions where comprehensive sex education is lacking, knowledge gaps contribute to the continued spread of HIV.

Cultural and language barriers, as well as insufficiently localized public health campaigns, further limit the effectiveness of outreach programs. Bridging these gaps requires a multifaceted strategy, including investment in healthcare infrastructure, community-based awareness initiatives, and integration of HIV testing into routine healthcare services. Closing the accessibility and awareness gap is crucial for improving early detection and reducing global HIV transmission rates.

Market Trends

Technological Innovation Driving Market Expansion

The HIV diagnostics market has been notably influenced by continuous advancements in testing technologies. One of the most transformative developments has been the rise of point-of-care testing (POCT) devices. These portable tools deliver rapid results-often within 30 minutes-enabling immediate clinical action and reducing transmission risks. POCT has been particularly valuable in resource-constrained environments lacking advanced laboratory infrastructure.

Nucleic acid testing (NAT) has further enhanced diagnostic accuracy by detecting the virus's genetic material directly, allowing for earlier identification and minimizing false-negative results. In parallel, next-generation sequencing (NGS) technologies have facilitated deeper understanding of HIV strain diversity, which is vital given the virus's high mutation rate. This knowledge supports the development of more targeted diagnostics and therapies.

Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based platforms, offer improved sensitivity and specificity. These tests can differentiate between HIV-1 and HIV-2 and are less susceptible to false positives.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Alere Inc.
  • Abbott Laboratories inc.
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • VIIV Healthcare
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Zyomtronix, Inc.
  • Mylan N.V.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH

Report Scope:

In this report, the Global HIV Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Diagnostics Market, By Product:

  • Consumables
  • Instruments
  • Software and Services

HIV Diagnostics Market, By Test Type:

  • Antibody Tests
  • Viral Load Tests
  • CD4 Test
  • Others

HIV Diagnostics Market, By Mode:

  • Self-Test
  • Lab-based

HIV Diagnostics Market, By End-use:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Home Settings

HIV Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.

Available Customizations:

Global HIV Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global HIV Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Instruments, Software and Services)
    • 5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
    • 5.2.3. By Mode (Self-Test, Lab-based)
    • 5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America HIV Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Test Type
    • 6.2.3. By Mode
    • 6.2.4. By End-use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States HIV Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Mode
        • 6.3.1.2.4. By End-use
    • 6.3.2. Mexico HIV Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Mode
        • 6.3.2.2.4. By End-use
    • 6.3.3. Canada HIV Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Mode
        • 6.3.3.2.4. By End-use

7. Europe HIV Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Test Type
    • 7.2.3. By Mode
    • 7.2.4. By End-use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France HIV Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Mode
        • 7.3.1.2.4. By End-use
    • 7.3.2. Germany HIV Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Mode
        • 7.3.2.2.4. By End-use
    • 7.3.3. United Kingdom HIV Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Mode
        • 7.3.3.2.4. By End-use
    • 7.3.4. Italy HIV Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Mode
        • 7.3.4.2.4. By End-use
    • 7.3.5. Spain HIV Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Mode
        • 7.3.5.2.4. By End-use

8. Asia-Pacific HIV Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Test Type
    • 8.2.3. By Mode
    • 8.2.4. By End-use
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China HIV Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Mode
        • 8.3.1.2.4. By End-use
    • 8.3.2. India HIV Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Mode
        • 8.3.2.2.4. By End-use
    • 8.3.3. South Korea HIV Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Mode
        • 8.3.3.2.4. By End-use
    • 8.3.4. Japan HIV Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Mode
        • 8.3.4.2.4. By End-use
    • 8.3.5. Australia HIV Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Mode
        • 8.3.5.2.4. By End-use

9. South America HIV Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Test Type
    • 9.2.3. By Mode
    • 9.2.4. By End-use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil HIV Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Mode
        • 9.3.1.2.4. By End-use
    • 9.3.2. Argentina HIV Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Mode
        • 9.3.2.2.4. By End-use
    • 9.3.3. Colombia HIV Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Mode
        • 9.3.3.2.4. By End-use

10. Middle East and Africa HIV Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Test Type
    • 10.2.3. By Mode
    • 10.2.4. By End-use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa HIV Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Mode
        • 10.3.1.2.4. By End-use
    • 10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Mode
        • 10.3.2.2.4. By End-use
    • 10.3.3. UAE HIV Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Mode
        • 10.3.3.2.4. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Thermo Fisher Scientific, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Alere Inc.
  • 14.3. Abbott Laboratories inc.
  • 14.4. Bristol-Myers Squibb Company
  • 14.5. Janssen Global Services, LLC
  • 14.6. Gilead Sciences, Inc.
  • 14.7. Merck & Co. Inc.
  • 14.8. VIIV Healthcare
  • 14.9. Beckman Coulter, Inc.
  • 14.10. Sysmex Europe SE
  • 14.11. Zyomtronix, Inc.
  • 14.12. Mylan N.V.
  • 14.13. F. Hoffmann-La Roche Ltd.
  • 14.14. Siemens Healthcare GmbH

15. Strategic Recommendations

16. About Us & Disclaimer